Clinical Trials and Research News Weekly Roundup | S2 E28 | Favipiravir Cut while Ivermectin Added

TrialSite News Weekly roundup

Delhi’s #COVID-19 Provider Lok Nayak Hospital Cuts #Favipiravir & Adds Ivermectin & Remdesivir for COVID-19 Patients: Lok Nayak Hospital is the national capital’s first COVID-19 only facility. Although Favipiravir was recently embraced in India by Glenmark Pharmaceuticals in the form of Fabiflu, this Delhi hospital has discontinued the use of the drug for COVID-19 patients. The well-known hospital has approved off label use of #Ivermectin for early-stage COVID-19 patients, as well as #Remdesivir, Tocilizumab, and plasma therapy.
Prominent Brazilian University Embarks on Phase 2 Ivermectin Clinical Trial: The Federal University of Sao Carlos, (UFSCar) a public research university located in Sao Carlos, in the state of Sao Paulo Brazil was established in 1968 and supports the education of over 15,000 undergraduates and about 4,700 graduate students. Ranked among the top 10 universities in Brazil, the Brazilian Ministry of Education assigned UFSCar a maximum teaching quality score. The university jus...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee